Amyloid A in Serum and Ascitic Fluid as a Novel Diagnostic Marker of Spontaneous Bacterial Peritonitis.
Adult
Ascitic Fluid
/ metabolism
Bacterial Infections
/ diagnosis
Biomarkers
/ metabolism
Blood Proteins
/ metabolism
C-Reactive Protein
/ metabolism
Female
Humans
Liver
/ immunology
Male
Middle Aged
Peritonitis
/ diagnosis
Reference Standards
Sensitivity and Specificity
Serum Amyloid A Protein
/ metabolism
Ascitic fluid
C-Reactive Protein (CRP)
Serum Amyloid
A (SAA)
Spontaneous Bacterial Peritonitis (SBP)
bacterial infections
diagnostic marker.
Journal
Anti-inflammatory & anti-allergy agents in medicinal chemistry
ISSN: 1875-614X
Titre abrégé: Antiinflamm Antiallergy Agents Med Chem
Pays: United Arab Emirates
ID NLM: 101462262
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
02
2019
revised:
13
03
2019
accepted:
21
03
2019
pubmed:
2
4
2019
medline:
23
1
2021
entrez:
2
4
2019
Statut:
ppublish
Résumé
Diagnosis of Spontaneous Bacterial Peritonitis (SBP) depends mainly on ascetic fluid culture which may be negative in spite of the clinical suggestion of SBP and high ascetic fluid neutrophilic count. This study aimed to evaluate the biological importance of amyloid A biomarker in both serum and ascetic fluid to diagnose SBP as early as possible and to compare it to other markers (C-reactive protein (CRP), and the neutrophil-to-lymphocyte ratio (NLR)). This study included 37 patients with hepatic ascites; twenty-two of them had SBP, and 15 patients did not have SBP. Serum and ascetic fluid amyloid A, ascetic fluid neutrophil, C-reactive protein, and neutrophil-to-lymphocyte ratio were measured in all subjects before the start of antimicrobial chemotherapy to the infected ones. Both the serum and ascetic fluid amyloid and also, CRP were significantly higher in patients infected with ascetic fluid than others. The cut-off point of serum amyloid A for early detection of SBP was 9.25ug/ml with the high sensitivity and specificity. For ascetic amyloid A, the sensitivity and specificity were 90.09% and 60% at cut-off point 2.85ug/ml, respectively. Amyloid A in serum and ascitic fluid can be considered as a good biomarker for early diagnosis of SBP.
Sections du résumé
BACKGROUND
BACKGROUND
Diagnosis of Spontaneous Bacterial Peritonitis (SBP) depends mainly on ascetic fluid culture which may be negative in spite of the clinical suggestion of SBP and high ascetic fluid neutrophilic count.
AIMS
OBJECTIVE
This study aimed to evaluate the biological importance of amyloid A biomarker in both serum and ascetic fluid to diagnose SBP as early as possible and to compare it to other markers (C-reactive protein (CRP), and the neutrophil-to-lymphocyte ratio (NLR)).
METHODS
METHODS
This study included 37 patients with hepatic ascites; twenty-two of them had SBP, and 15 patients did not have SBP. Serum and ascetic fluid amyloid A, ascetic fluid neutrophil, C-reactive protein, and neutrophil-to-lymphocyte ratio were measured in all subjects before the start of antimicrobial chemotherapy to the infected ones.
RESULTS
RESULTS
Both the serum and ascetic fluid amyloid and also, CRP were significantly higher in patients infected with ascetic fluid than others. The cut-off point of serum amyloid A for early detection of SBP was 9.25ug/ml with the high sensitivity and specificity. For ascetic amyloid A, the sensitivity and specificity were 90.09% and 60% at cut-off point 2.85ug/ml, respectively.
CONCLUSION
CONCLUSIONS
Amyloid A in serum and ascitic fluid can be considered as a good biomarker for early diagnosis of SBP.
Identifiants
pubmed: 30931865
pii: AIAAMC-EPUB-97721
doi: 10.2174/1871523018666190401154447
pmc: PMC7475799
doi:
Substances chimiques
Biomarkers
0
Blood Proteins
0
Serum Amyloid A Protein
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
140-148Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Références
J Pediatr Gastroenterol Nutr. 2014 Jan;58(1):96-8
pubmed: 24051480
Ann Intern Med. 1964 Apr;60:568-80
pubmed: 14138877
Gastroenterol Res Pract. 2016;2016:4013052
pubmed: 27340399
Adv Med Sci. 2011;56(1):13-7
pubmed: 21536540
Ann Lab Med. 2013 Nov;33(6):449-54
pubmed: 24205495
BMC Gastroenterol. 2015 Oct 23;15:146
pubmed: 26498833
Aliment Pharmacol Ther. 2011 Jan;33(2):275-84
pubmed: 21083594
N Engl J Med. 1999 Feb 11;340(6):448-54
pubmed: 9971870
World J Gastroenterol. 2013 Feb 28;19(8):1271-7
pubmed: 23483064
Trop Gastroenterol. 2013 Jan-Mar;34(1):7-13
pubmed: 23923368
Hepatogastroenterology. 2009 Mar-Apr;56(90):452-5
pubmed: 19579619
Arch Surg. 1997 Dec;132(12):1263-9; discussion 1269-70
pubmed: 9403528
J Hepatol. 2011 Sep;55(3):574-581
pubmed: 21236309
J Exp Med. 1994 Jul 1;180(1):203-9
pubmed: 7516407
Immunology. 1982 Aug;46(4):737-44
pubmed: 6921153
J Hepatol. 2014 Jun;60(6):1310-24
pubmed: 24530646
J Hepatol. 2000 Jan;32(1):142-53
pubmed: 10673079
Gastroenterology. 2008 Sep;135(3):803-7
pubmed: 18590731
Eur J Gastroenterol Hepatol. 2006 May;18(5):525-30
pubmed: 16607149
World J Hepatol. 2015 Mar 27;7(3):304-14
pubmed: 25848460
Liver Int. 2009 Nov;29(10):1538-42
pubmed: 19659507
Gut. 1963 Dec;4:394-8
pubmed: 14084751
Hepatology. 2013 Apr;57(4):1651-3
pubmed: 23463403
J Hepatol. 2010 Sep;53(3):397-417
pubmed: 20633946
Am J Pathol. 1994 Sep;145(3):650-60
pubmed: 8080047
BMC Infect Dis. 2015 Feb 13;15:55
pubmed: 25887691
Scand J Immunol. 2000 Feb;51(2):141-6
pubmed: 10652160
Curr Drug Targets. 2019;20(4):380-387
pubmed: 30246636
Eur J Gastroenterol Hepatol. 2016 Dec;28(12):1450-1454
pubmed: 27512927
Nutrition. 2010 Oct;26(10):1021-8
pubmed: 20036516
Pak J Med Sci. 2016 Nov-Dec;32(6):1484-1488
pubmed: 28083050
J Leukoc Biol. 2005 Aug;78(2):325-37
pubmed: 15817707
Int J Cardiol. 2004 Oct;97(1):155-6
pubmed: 15336829
Mediators Inflamm. 2006;2006(1):47297
pubmed: 16864904